The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma

Journal of Gynecologic Oncology

Volumn 21, Issue 1, 2010, Pages 50-55

  Kim, Hyunjin ^a   Choi, Dong Soon ^b   Chang, Suk Joon ^a   Ho Han, Jae ^a   Min, Churl K ^a   Chang, Ki Hong ^a   Ryu, Hee Sug ^a  

^a Ajou University School of Medicine   (South Korea)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Endometrial cancer; Endometrial hyperplasia; Syndecan 1

Indexed keywords

FORMALDEHYDE; PARAFFIN; SYNDECAN 1;

ADULT; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALIDITY; PROTEIN EXPRESSION;

EID: 77953419816     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.1.50     Document Type: Article

References (24)

1. Lee SE, Kim JW, Park NH, Song YS, Kang SB, Lee HR Contemporary trends of endometrial cancer in Korean women. Korean J Gynecol Oncol 2005; 16: 215-220
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130
3. Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA Nogales F, Tavassoli FA. Tumors of the uterine corpus: epithelial tumors and related lesions. In: Tavassoli FA, Stratton MR, editors. WHO classification of tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003. p. 221-232
4. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56: 403-412
5. 5. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L Diener-West M, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. AmJ Surg Pathol 1998; 22: 1012-1019 (Pubitemid 28364502)
6. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
7. 7. Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, et al. Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer 2007; 121: 741-750 (Pubitemid 47106202)
8. 8. Anttonen A, Kajanti M, Heikkila R Jalkanen M, Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. BrJ Cancer 1999; 79: 558-564 (Pubitemid 29046236)
9. 9. Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, Yanagishita M, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 2001; 92: 1062-1073 (Pubitemid 33041175)
10. 10. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi R Grenman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 1997; 117: 312-315 (Pubitemid 27151781)
11. 11. Matsumoto A Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997; 74: 482-491 (Pubitemid 27486504)
12. 12. Anttonen A, Heikkila R Kajanti M, Jalkanen M, Joensuu H. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 2001; 32: 297-305. (Pubitemid 32487690)
13. 13. Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, et al. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 2001; 92: 1074-1081 (Pubitemid 33041176)
14. Numa F, Hirabayashi K, Kawasaki K, Sakaguchi Y, Sugino N, Suehiro Y, et al. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int J Oncol 2002; 20: 39-43.
15. Chen CL Ou DL Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 2006; 37: 1279-1285
16. 16. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L Angelo Mauri F, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-483 (Pubitemid 36885986)
17. 17. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003; 55: 20-29 (Pubitemid 36397741)
18. 18. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003; 43: 157-164 (Pubitemid 36963160)
19. 19. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-393 (Pubitemid 23001002)
20. 20. Soukka T, Pohjola J, Inki P, Happonen RP. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med 2000; 29: 308-313 (Pubitemid 30459302)
21. 21. Mukunyadzi R Liu K, Hanna EY, Suen JY, Fan CY. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 2003; 16: 796-801. (Pubitemid 37011075)
22. 22. Kurokawa H, Matsumoto S, Murata T, Yamashita Y, Tomoyose T, Zhang M, et al. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia. J Oral Pathol Med 2003; 32: 513-521 (Pubitemid 37175003)
23. 23. Hunter JE, Tritz DE, Howell MG, DePriest PD, Gallion HH, Andrews SJ, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol 1994; 55: 66-71. (Pubitemid 24336120)
24. Amant F, Moerman R Neven R Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505.